Barinthus Biotherapeutics plc
BRNS
$0.73
$0.011.22%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | 4,381.74% | 1,766.46% | 106.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | 4,381.74% | 1,766.46% | 106.21% |
| Cost of Revenue | -41.84% | 70.63% | 67.32% | 115.13% | 3.96% |
| Gross Profit | -69.68% | 64.17% | 60.29% | 23.79% | 46.71% |
| SG&A Expenses | -26.51% | 37.21% | -10.29% | -40.14% | -12.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 48.80% | 61.17% | -15,700.00% | -- | -- |
| Total Operating Expenses | -28.80% | 1.24% | -15.61% | -25.03% | -17.58% |
| Operating Income | 11.86% | 20.54% | 34.70% | 42.84% | 27.88% |
| Income Before Tax | -29.47% | -6.46% | 10.89% | 19.99% | 28.00% |
| Income Tax Expenses | 86.74% | 96.80% | 98.88% | 98.57% | 79.71% |
| Earnings from Continuing Operations | -31.21% | -8.83% | 7.67% | 16.70% | 25.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 23.64% | 0.00% | 0.00% | 9.00% | -28.57% |
| Net Income | -31.22% | -8.84% | 7.68% | 16.73% | 25.14% |
| EBIT | 11.86% | 20.54% | 34.70% | 42.84% | 27.88% |
| EBITDA | 13.30% | 23.06% | 36.87% | 44.52% | 29.27% |
| EPS Basic | -26.50% | -5.00% | 10.56% | 18.88% | 26.76% |
| Normalized Basic EPS | 14.12% | 24.07% | 37.37% | 44.61% | 29.71% |
| EPS Diluted | -26.19% | -4.91% | 10.60% | 19.01% | 26.67% |
| Normalized Diluted EPS | 14.12% | 24.07% | 37.37% | 44.61% | 29.71% |
| Average Basic Shares Outstanding | 3.60% | 3.39% | 2.97% | 2.51% | 2.31% |
| Average Diluted Shares Outstanding | 3.60% | 3.39% | 2.97% | 2.51% | 2.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |